Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2005-10-17
pubmed:abstractText
To clarify the essential role of NKT cells in allergy, we investigated the contribution of NKT cells to the pathogenesis of eosinophilic airway inflammation using alpha-galactosylceramide (alpha-GalCer), a selective ligand for NKT cells. Although continuous administration of alpha-GalCer during ovalbumin (OVA) sensitization increased OVA-specific IgE levels and worsened eosinophil inflammation, a single administration of alpha-GalCer at the time of OVA challenge completely prevented eosinophilic infiltration in wild-type mice. This inhibitory effect of alpha-GalCer was associated with a decrease in airway hyperresponsiveness, an increase in IFN-gamma, and decreases in IL-4, IL-5 and IL-13 levels in the bronchoalveolar lavage fluids. Analysis of lung lymphocytes revealed that production of IFN-gamma increased in NK cells, but not in T or NKT cells, following alpha-GalCer administration. Induction of vascular cell adhesion molecule-1 in the lungs of wild-type mice was also significantly attenuated by treatment with alpha-GalCer. These effects of alpha-GalCer were abrogated in J alpha281-/- mice, which lack NKT cells, and in wild-type mice treated with anti-IFN-gamma Ab. Hence, our data indicate that alpha-GalCer suppresses allergen-induced eosinophilic airway inflammation, possibly by inducing a Th1 bias that results in inhibition of eosinophil adhesion to the lung vessels.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0014-2980
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2803-14
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:16163669-Animals, pubmed-meshheading:16163669-Blotting, Western, pubmed-meshheading:16163669-Bronchial Hyperreactivity, pubmed-meshheading:16163669-Bronchoalveolar Lavage Fluid, pubmed-meshheading:16163669-Collagen Type I, pubmed-meshheading:16163669-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:16163669-Eosinophils, pubmed-meshheading:16163669-Flow Cytometry, pubmed-meshheading:16163669-Galactosylceramides, pubmed-meshheading:16163669-Inflammation, pubmed-meshheading:16163669-Interferon-gamma, pubmed-meshheading:16163669-Interleukin-13, pubmed-meshheading:16163669-Interleukin-4, pubmed-meshheading:16163669-Interleukin-5, pubmed-meshheading:16163669-Killer Cells, Natural, pubmed-meshheading:16163669-Lung, pubmed-meshheading:16163669-Mice, pubmed-meshheading:16163669-Mice, Mutant Strains, pubmed-meshheading:16163669-Ovalbumin, pubmed-meshheading:16163669-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:16163669-T-Lymphocytes, pubmed-meshheading:16163669-Vascular Cell Adhesion Molecule-1
pubmed:year
2005
pubmed:articleTitle
Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide.
pubmed:affiliation
Department of Pulmonary Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan. mk01a231@md.tsukuba.ac.jp
pubmed:publicationType
Journal Article